Literature DB >> 28976019

The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.

Rimona S Weil1,2, Katerina Pappa3, Rachel N Schade1, Anette E Schrag4, Bahador Bahrami3, Dietrich S Schwarzkopf3,5,6, Sebastian J Crutch2, Aidan G O'Keeffe7, Huw R Morris1,4.   

Abstract

Entities:  

Keywords:  Parkinson's disease; biomarker; cognition; dementia; vision

Mesh:

Year:  2017        PMID: 28976019      PMCID: PMC5765443          DOI: 10.1002/mds.27176

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


× No keyword cloud information.
There are no robust features to predict which patients with Parkinson's disease (PD) will develop dementia. Those with involvement of visual processing regions are at highest risk of dementia.1, 2, 3 However, current measures of visuoperception are poorly sensitive.4 We have developed a sensitive test of visuoperception based on the clinical observation that patients with PD have difficulty reading distorted CAPTCHA (completely automated public Turing test to tell computers and humans apart) images.5

Methods

Participants

Twenty patients with PD and 11 age‐matched controls without eye disease or dementia were recruited. Clinical and detailed neuropsychological assessment was performed (Supplemental Table 1). Participants gave written informed consent. The study was approved by the local Research Ethics Committee.

Procedure

Images of cats and dogs were skewed by a variable amount (11 levels, 0‐5 arbitrary units [a.u.]) and combined with white noise (Fig. 1A and Supplementary Methods). On each trial the skewed image was shown for 280 milliseconds. Participants indicated whether the image was a cat or dog using the keypad (4 runs, each with 100 trials; 25 minutes in total, preceded by a practice session).
Figure 1

(A) Left: Cats‐and‐Dogs test, example skewed image. A dog is shown. Images in this task varied in the amount of skew, and performance at each level of skew was recorded. Right: control task, example image with added visual noise. A cat is shown. Images in this task varied in the amount of visual noise, and performance at each level of noise was recorded. (B) Method for determining performance in the Cats‐and‐Dogs test; psychophysical curves for 2 example participants are shown, one with PD (black), one without (gray). Percentage correct is shown for each level of skew. Performance is defined as the skew level corresponding to 75% (midway between perfect 100% and guess at 50%) and is marked for each of the participants. The same method was used to determine performance in the control task, with amount of noise plotted against percentage correct. (arbitrary units [a.u.]). (C) Left: performance in the Cats‐and‐Dogs test in patients with Parkinson's disease and controls. Patients with Parkinson's disease performed worse than healthy controls, with lower thresholds to correctly identify skewed images. Wider variation in performance was also seen in patients with Parkinson's disease. Right: performance in the control test in patients with Parkinson's disease and controls. There was no significant difference in performance in this task between patients with Parkinson's disease and healthy controls. (a.u.). (D) Relationship between performance in the Cats‐and‐Dogs test and overall cognition (Montreal Cognitive Assessment).

(A) Left: Cats‐and‐Dogs test, example skewed image. A dog is shown. Images in this task varied in the amount of skew, and performance at each level of skew was recorded. Right: control task, example image with added visual noise. A cat is shown. Images in this task varied in the amount of visual noise, and performance at each level of noise was recorded. (B) Method for determining performance in the Cats‐and‐Dogs test; psychophysical curves for 2 example participants are shown, one with PD (black), one without (gray). Percentage correct is shown for each level of skew. Performance is defined as the skew level corresponding to 75% (midway between perfect 100% and guess at 50%) and is marked for each of the participants. The same method was used to determine performance in the control task, with amount of noise plotted against percentage correct. (arbitrary units [a.u.]). (C) Left: performance in the Cats‐and‐Dogs test in patients with Parkinson's disease and controls. Patients with Parkinson's disease performed worse than healthy controls, with lower thresholds to correctly identify skewed images. Wider variation in performance was also seen in patients with Parkinson's disease. Right: performance in the control test in patients with Parkinson's disease and controls. There was no significant difference in performance in this task between patients with Parkinson's disease and healthy controls. (a.u.). (D) Relationship between performance in the Cats‐and‐Dogs test and overall cognition (Montreal Cognitive Assessment).

Control Task

Images were prepared as above (but not skewed) with a varying proportion of visual noise added (11 levels), in a similar procedure with 2 runs, 100 trials per run, 15 PD patients and 10 age‐matched controls (Fig. 1A; Supplemental Table 2).

Analysis

Demographic and neuropsychological data were compared using Welch's t and chi‐square tests. For each participant a psychophysical curve was generated for the Cats‐and‐Dogs test and control task, a sigmoid curve fitted, and 75% performance threshold determined (Fig. 1B). Bonferroni‐corrected P < 0.05 was considered significant. Linear regression was used to examine relationships between the Cats‐and‐Dogs test and other variables. We used a recently described algorithm, modified to include available clinical variables, to calculate each participant's risk of dementia. This combines cross‐sectional data including age, Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) motor score, depression, and REM‐sleep behavior scores to calculate the 2‐year risk of cognitive impairment.6

Results

Patients with PD performed worse than controls at identifying skewed images: PD mean threshold, 1.92 ± 0.5 a.u; controls, 2.48 ± 0.26 a.u.; t 29.0 = −4.06, P = 0.00034 (Fig. 1C). There was no other significant difference in cognitive or clinical tests, including the standard visuoperceptual tests, between PD patients and controls (excluding MDS‐UPDRS; Supplemental Table 1). Mean reaction times and visual acuity did not differ significantly between the groups. There was no difference in the control task (white noise) between PD patients and controls. The Cats‐and‐Dogs test correlated with higher age (estimate, −0.033 ± 0.009; P = 0.00093) and vascular risk, after adjustment for PD (estimate, −0.026 ± 0.006; P = 0.021). Even after age adjustment, it correlated with overall cognitive performance (estimate, 0.17 ± 0.05; P = 0.0037) and language, assessed with the Graded Naming Test (estimate, 0.076 ± 0.017; P = 0.00015; Fig. 1D) but not standard visuoperceptual tests (Supplemental Table 5). It also correlated with 2‐year cognitive impairment risk, calculated using cross‐sectional data6 (R 2 = 0.22, P = 0.0078; Supplemental Fig. 1).

Discussion

We present pilot data suggesting that identifying skewed images in the Cats‐and‐Dogs test is a sensitive measure of visuoperception in early‐stage PD, with greater sensitivity than standard cognitive and visuospatial tests. Performance on the Cats‐and‐Dogs test correlated with age, vascular risk, and cognitive performance but not with standard visuoperception tests, most likely because participants were at ceiling in these tests. Performance in this test also correlated with a prediction score for cognitive impairment in PD, suggesting that it may have utility as an early marker of cognitive decline, consistent with the literature of PD patients with involvement of visual‐processing regions being at the highest risk of dementia.1, 2, 3 However, our study will require replication in larger cross‐sectional and longitudinal numbers. Additional Supporting Information may be found in the online version of this article at the publisher's website. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file. Supporting Information Click here for additional data file.
  6 in total

1.  Pathological α-synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology.

Authors:  Jon B Toledo; Pallavi Gopal; Kevin Raible; David J Irwin; Johannes Brettschneider; Samantha Sedor; Kayla Waits; Susana Boluda; Murray Grossman; Vivianna M Van Deerlin; Edward B Lee; Steven E Arnold; John E Duda; Howard Hurtig; Virginia M-Y Lee; Charles H Adler; Thomas G Beach; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2015-12-31       Impact factor: 17.088

2.  Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study.

Authors:  Nicolaas I Bohnen; Robert A Koeppe; Satoshi Minoshima; Bruno Giordani; Roger L Albin; Kirk A Frey; David E Kuhl
Journal:  J Nucl Med       Date:  2011-05-13       Impact factor: 10.057

3.  Primary vision and facial emotion recognition in early Parkinson's disease.

Authors:  Géraldine Hipp; Nico J Diederich; Vannina Pieria; Michel Vaillant
Journal:  J Neurol Sci       Date:  2014-01-09       Impact factor: 3.181

4.  reCAPTCHA: human-based character recognition via Web security measures.

Authors:  Luis von Ahn; Benjamin Maurer; Colin McMillen; David Abraham; Manuel Blum
Journal:  Science       Date:  2008-08-14       Impact factor: 47.728

5.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort.

Authors:  Caroline H Williams-Gray; Sarah L Mason; Jonathan R Evans; Thomas Foltynie; Carol Brayne; Trevor W Robbins; Roger A Barker
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-06-18       Impact factor: 10.154

6.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.

Authors:  Anette Schrag; Uzma Faisal Siddiqui; Zacharias Anastasiou; Daniel Weintraub; Jonathan M Schott
Journal:  Lancet Neurol       Date:  2016-11-18       Impact factor: 44.182

  6 in total
  17 in total

1.  The TAS Test project: a prospective longitudinal validation of new online motor-cognitive tests to detect preclinical Alzheimer's disease and estimate 5-year risks of cognitive decline and dementia.

Authors:  Jane Alty; Quan Bai; Renjie Li; Katherine Lawler; Rebecca J St George; Edward Hill; Aidan Bindoff; Saurabh Garg; Xinyi Wang; Guan Huang; Kaining Zhang; Kaylee D Rudd; Larissa Bartlett; Lynette R Goldberg; Jessica M Collins; Mark R Hinder; Sharon L Naismith; David C Hogg; Anna E King; James C Vickers
Journal:  BMC Neurol       Date:  2022-07-18       Impact factor: 2.903

2.  REM sleep behaviour disorder: an early window for prevention in neurodegeneration?

Authors:  Rimona S Weil; Huw R Morris
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

3.  Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.

Authors:  Angeliki Zarkali; Peter McColgan; Louise-Ann Leyland; Andrew J Lees; Rimona S Weil
Journal:  Mov Disord       Date:  2021-01-09       Impact factor: 9.698

Review 4.  Mild Cognitive Impairment in Parkinson's Disease-What Is It?

Authors:  Rimona S Weil; Alyssa A Costantini; Anette E Schrag
Journal:  Curr Neurol Neurosci Rep       Date:  2018-03-10       Impact factor: 5.081

5.  Comparison of computer-key-hold-time and alternating-finger-tapping tests for early-stage Parkinson's disease.

Authors:  Boon Leong Lan; Jacob Hsiao Wen Yeo
Journal:  PLoS One       Date:  2019-06-27       Impact factor: 3.240

6.  Neuroimaging in Parkinson's disease dementia: connecting the dots.

Authors:  Rimona S Weil; Joey K Hsu; Ryan R Darby; Louis Soussand; Michael D Fox
Journal:  Brain Commun       Date:  2019-07-08

7.  Neural correlates of early cognitive dysfunction in Parkinson's disease.

Authors:  Rimona S Weil; Joel S Winston; Louise-Ann Leyland; Katerina Pappa; Ribeya B Mahmood; Huw R Morris; Geraint Rees
Journal:  Ann Clin Transl Neurol       Date:  2019-03-28       Impact factor: 4.511

8.  Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.

Authors:  Rimona S Weil; Dietrich S Schwarzkopf; Bahador Bahrami; Stephen M Fleming; Ben M Jackson; Tristam J C Goch; Ayse P Saygin; Luke E Miller; Katerina Pappa; Ivanna Pavisic; Rachel N Schade; Alastair J Noyce; Sebastian J Crutch; Aidan G O'Keeffe; Anette E Schrag; Huw R Morris
Journal:  Mov Disord       Date:  2018-02-23       Impact factor: 10.338

9.  Fiber-specific white matter reductions in Parkinson hallucinations and visual dysfunction.

Authors:  Angeliki Zarkali; Peter McColgan; Louise-Ann Leyland; Andrew J Lees; Geraint Rees; Rimona S Weil
Journal:  Neurology       Date:  2020-02-24       Impact factor: 9.910

10.  Visual tests predict dementia risk in Parkinson disease.

Authors:  Louise-Ann Leyland; Fion D Bremner; Ribeya Mahmood; Sam Hewitt; Marion Durteste; Molly R E Cartlidge; Michelle M-M Lai; Luke E Miller; Ayse P Saygin; Pearse A Keane; Anette E Schrag; Rimona S Weil
Journal:  Neurol Clin Pract       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.